Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer

Ovarian Cancer Clinical Trial

Official title:

A Phase I/Ib Study of Paclitaxel in Combination With VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Advanced Ovarian Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01778803
• Other study ID #: VS-6063-101
• Status: Completed
• Phase: Phase 1
• First received: January 22, 2013
• Last updated: May 15, 2017
• Start date: February 26, 2013
• Est. completion date: February 23, 2015

Study information

• Verified date: January 2017
• Source: Verastem, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase I/Ib, open-label, multicenter, dose-escalation trial of paclitaxel in combination with defactinib (VS-6063), a focal adhesion kinase inhibitor, in patients with advanced ovarian cancer. This clinical study is comprised of 2 parts: Phase I (Dose Escalation) and Phase Ib (Expansion). The purpose of this study is to assess assess the safety (including the recommended phase 2 dose), the pharmacokinetics, and the anti-cancer activity of defactinib (VS-6063) when administered in combination with paclitaxel. Pharmacodynamic effects will also be examined in tumor biopsies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: February 23, 2015
• Est. primary completion date: February 23, 2015
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Able to provide signed and dated informed consent prior to initiation of any study procedures.

2. Female subjects aged = 18 years.

3. Advanced or refractory ovarian cancer, confirmed histologically.

4. Subjects may have received up to 4 prior lines of chemotherapy for their metastatic disease.

5. All persistent clinically significant toxicities from prior chemotherapy must be = Grade 1.

6. ECOG performance status of 0 or 1 (refer to Appendix A), measured within 72 hours before the start of treatment.

7. Predicted life expectancy of = 3 months.

8. Adequate renal function [creatinine = 1.5x ULN (upper limit of normal)] or GFR of = 50mL/min.

9. Adequate hepatic function (total bilirubin = 1.5x ULN for the institution; AST [aspartate transaminase] and ALT [alanine transaminase] = 3x ULN, or = 5x ULN if due to liver involvement by tumor).

10. Adequate bone marrow function (hemoglobin = 9.0 g/dL; platelets= 100 x109cells/L; absolute neutrophil count = 1.5x109 cells/L).

11. Corrected QT interval (QTc) < 470 ms (as calculated by the Fridericia correction formula).

12. Negative pregnancy test for females of child-bearing potential; must be surgically sterile, postmenopausal, or willing and able to be compliant with a contraceptive regimen (double barrier birth control) during and for 3 months after the treatment period.

13. Willing and able to participate in the trial and comply with all trial requirements.

Exclusion Criteria:

1. Gastrointestinal (GI) condition which could interfere with the swallowing or absorption of study medication.

2. Uncontrolled or severe concurrent medical condition (including uncontrolled brain metastases). Stable brain metastases either treated or being treated with a stable dose of steroids/anticonvulsants, with no dose change within 28 days prior to the first dose of study drug, will be allowed.

3. History of upper gastrointestinal bleeding, ulceration, or perforation within 12 months prior to the first dose of study drug.

4. Known history of Gilbert's Syndrome.

5. Known history of stroke or cerebrovascular accident within 6 months prior to the first dose of study drug.

6. Subjects with known infection with human immunodeficiency virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS) (testing not required).

7. Subjects with Hepatitis A, B or C (testing not required).

8. Subjects being actively treated for a secondary malignancy.

9. Cancer-directed therapy (chemotherapy, radiotherapy, hormonal therapy, biologic or immunotherapy, etc.) within 28 days of the first dose of study drug or 5 half-lives, whichever is shorter.

10. Major surgery within 28 days prior to the first dose of study drug.

11. Use of an investigational drug within 28 days or 5 half-lives (whichever is shorter) prior to the first dose of study drug. A minimum of 10 days between termination of the investigational drug and administration of the study treatment is required. In addition, any drug-related toxicity except alopecia should have recovered to grade 1 or less.

12. Pregnant or breastfeeding.

13. Any evidence of serious active infections.

14. Uncontrolled or severe cardiovascular disease, including myocardial infarct or unstable angina within 6 months prior to study treatment, New York Heart Association (NYHA) Class II or greater congestive heart failure, serious arrhythmias requiring medication for treatment, clinically significant pericardial disease, or cardiac amyloidosis.

15. Uncontrolled intercurrent illness including symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Related Conditions & MeSH terms

• Ovarian Cancer
• Ovarian Neoplasms

Intervention

Drug:
• defactinib

• Paclitaxel

Locations

Country	Name	City	State
United States	Sarah Cannon Research Institute	Nashville	Tennessee
United States	University of Oklahoma	Oklahoma City	Oklahoma
United States	Florida Cancer Specialists	Sarasota	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Verastem, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Evaluate biomarkers of defactinib (VS-6063) activity	Pre and post dose biomarkers (including but not limited to FAK and phospho-FAK, as well as specific markers for cell cycle inhibition, apoptosis and cancer stem cells) in archival tumor tissue and new biopsy samples	Day 1 and Day 10 of treatment
Other	Examine if the tumor expression status correlates with response to defactinib (VS-6063) therapy	Tumor expression status (pFAK and other biomarkers) compared with response to defactinib, as determined by Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1	From start of treatment to end of treatment, an expected average of 12 weeks
Primary	Number of patients experiencing treatment-related adverse events as assessed by CTCAE v4.03 (Common Toxicity Criteria for Adverse Effects)during the study (safety and tolerability).	Adverse events and their frequency, duration and severity, as determined based on CTCAE 4.03	From start of treatment to end of treatment, an expected average of 12 weeks
Primary	Determine the recommended phase 2 dose (RP2D) based on a combination of maximum tolerated dosed (MTD), review of adverse event data and review of AUC, Tmax and t1/2 obtained from PK data during the dose escalation phase of the study.	The RP2D will be determined based on the maximum tolerated dose (MTD) of defactinib (VS-6063) in combination with paclitaxel as determined by number of participants with dose limiting toxicities (DLTs) related to defactinib in combination with paclitaxel	From start of treatment to end of cycle 1 (4 week cycles)
Secondary	Proportion of patients treated with paclitaxel and defactinib (VS-6063) with progression-free survival using Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1	Response rate and progression-free survival, as determined by Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1	Every 2 cycles up to end of treatment, an expected average of 12 weeks
Secondary	Pharmacokinetics (PK) estimates of defactinib (VS-6063) when co-administered with paclitaxel, AUC (Area Under Curve) 0-t.	Plasma concentration of defactinib (VS-6063)	Time points at Day 1 and Day 15 in Cycle 1
Secondary	Pharmacokinetics (PK) estimates of defactinib (VS-6063) when co-administered with paclitaxel, maximum concentrations (Cmax)	Plasma concentration of defactinib (VS-6063)	Time points at Day 1 and Day 15 in Cycle 1
Secondary	Pharmacokinetics (PK) estimates of defactinib (VS-6063) when co-administered with paclitaxel, Time to maximum concentrations (Tmax)	Plasma concentration of defactinib (VS-6063)	Time points at Day 1 and Day 15 in Cycle 1
Secondary	Pharmacokinetics (PK) estimates of defactinib (VS-6063) when co-administered with paclitaxel, , estimates of concentration 1/2 life (T1/2)	Plasma concentration of defactinib (VS-6063)	Time points at Day 1 and Day 15 in Cycle 1